Delineation of apoptotic genes for synergistic apoptosis of lexatumumab and anthracyclines in human renal cell carcinoma cells by polymerase chain reaction array

Anti-Cancer Drugs

Volumn 23, Issue 4, 2012, Pages 445-454

  Jin, Xinghua ^a,b   Wu, Xiu Xian ^b   Jin, Chenglou ^b,c   Inui, Masashi ^b   Sugimoto, Mikio ^b   Kakehi, Yoshiyuki ^b  

^a QIQIHAR MEDICAL UNIVERSITY   (China)

^b KAGAWA UNIVERSITY   (Japan)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

anthracyclines; apoptosis; lexatumumab; polymerase chain reaction array; renal cell carcinoma; tumor necrosis factor related apoptosis inducing ligand receptor 2

Indexed keywords

ANTHRACYCLINE DERIVATIVE; APOPTOSIS REGULATORY PROTEIN; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BCL2 ANTAGONIST 1 PROTEIN; BCL2 ASSOCIATED ATHANOGENE 3 PROTEIN; CASPASE 10; CASPASE 3; CASPASE 5; CASPASE 6; CASPASE 8; CASPASE 9; CD40 LIGAND; CIDEA PROTEIN; FAS ANTIGEN; FAS LIGAND; INTERLEUKIN 1BETA CONVERTING ENZYME; LEXATUMUMAB; LYMPHOTOXIN; MESSENGER RNA; PIRARUBICIN; PROTEIN BAX; PROTEIN BCL 10; PROTEIN BCL 2; PROTEIN BID; PROTEIN BNIP3; PYCARD PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 4; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG POTENTIATION; GENE CONTROL; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, RENAL CELL; CASPASES; CELL LINE, TUMOR; DOXORUBICIN; DRUG SYNERGISM; EPIRUBICIN; HUMANS; KIDNEY NEOPLASMS; POLYMERASE CHAIN REACTION; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84858296048     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32834fd796     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin 2009; 59:225-249.
2. Lilleby W, Fossa SD. Chemotherapy in metastatic renal cell cancer. World J Urol 2005; 23:175-179. (Pubitemid 41136038)
3. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol 2000; 27:177-186. (Pubitemid 30205372)
4. Vogelzang NJ. Treatment options in metastatic renal carcinoma: an embarrassment of riches. J Clin Oncol 2006; 24:1-3. (Pubitemid 46630483)
5. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5:157-163. (Pubitemid 29068521)
6. Hao C, Song JH, Hsi B, Lewis J, Song DK, Petruk KC, et al. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res 2004; 64:8502-8506. (Pubitemid 39552059)
7. Pan G, Ni J,Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277:815-818. (Pubitemid 27366732)
8. Van Geelen CM, Pennarun B, Le PT, de Vries EG, de Jong S. Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5. BMC Cancer 2011; 11:39.
9. Xie ZH, Quan MF, Liu F, Cao JG, Zhang JS. 5-Allyl-7- gendifluoromethoxychrysin enhances TRAIL-induced apoptosis in human lung carcinoma A549 cells. BMC Cancer 2011; 11:322.
10. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281:1305-1308. (Pubitemid 28406815)
11. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273:14363-14367. (Pubitemid 28319153)
12. Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci 2004; 95: 777-783. (Pubitemid 39545582)
13. Chuntharapai A, Dodge K, Grimmer K, Schroeder K, Marsters SA, Koeppen H, et al. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 2001; 166:4891-4898. (Pubitemid 32280698)
14. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001; 7:954-960. (Pubitemid 32756434)
15. Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R, Zhou T. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 2003; 22:2034-2044. (Pubitemid 36523640)
16. Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005; 92:1430-1441. (Pubitemid 40705010)
17. Zeng Y, Wu XX, Fiscella M, Shimada O, Humphreys R, Albert V, et al. Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo. Int J Oncol 2006; 28:421-430.
18. Wu XX, Jin XH, Zeng Y, El Hamed AM, Kakehi Y. Low concentrations of doxorubicin sensitize human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression. Cancer Sci 2007; 98: 1969-1976. (Pubitemid 350002205)
19. Wu XX, Mizutani Y, Kakehi Y, Yoshida O, Ogawa O. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin. Cancer Res 2000; 60:2912-2918.
20. Wu XX, Kakehi Y, Mizutani Y, Nishiyama H, Kamoto T, Megumi Y, et al. Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells. Int J Cancer 2003; 104:409-417. (Pubitemid 36323909)
21. Wu XX, Ogawa O, Kakehi Y. Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine. Int J Oncol 2004; 24:1489-1497.
22. Wu XX, Kakehi Y, Mizutani Y, Lu J, Terachi T, Ogawa O. Activation of caspase-3 in renal cell carcinoma cells by anthracyclines or 5-fluorouracil. Int J Oncol 2001; 19:19-24.
23. Wu XX, Kakehi Y. Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by cisplatin. Clin Cancer Res 2009; 15: 2039-2047.
24. Rieger J, Naumann U, Glaser T, Ashkenazi A, Weller M. APO2 ligand: a novel lethal weapon against malignant glioma? FEBS Lett 1998; 427: 124-128. (Pubitemid 28210109)
25. Parsons MJ, Vertino PM. Dual role of TMS1/ASC in death receptor signaling. Oncogene 2006; 25:6948-6958. (Pubitemid 44684835)
26. Li YH, Lei T, Chen XD, Chen QZ, Huang X, Chen YF, et al. Molecular cloning, chromosomal location and expression pattern of porcine CIDEa and CIDEc. Mol Bil Rep 2009; 36:575-582.
27. Berenbaum MC. Synergy, additivism and antagonism in immunosuppression. Clin Exp Immunol 1977; 28:1-18. (Pubitemid 8081042)
28. Gibson SB, Oyer R, Spalding AC, Anderson SM, Johnson GL. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol 2000; 20:205-212. (Pubitemid 30002562)
29. Schrader AJ, Hofmann R. Metastatic renal cell carcinoma: recent advances and current therapeutic options. Anticancer Drugs 2008; 19:235-245.
30. Georgakis GV, Li Y, Humphreys R, Andreeff M, O'Brien S, Younes M, et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomibinduced cell death. Br J Haematol 2005; 130:501-510. (Pubitemid 43899752)
31. Buchsbaum DJ, Zhou T, Grizzle WE, Oliver PG, Hammond CJ, Zhang S, et al. Antitumor efficacy of TRA-8 Anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 2003; 9:3731-3741. (Pubitemid 37169242)
32. Straughn JM Jr, Oliver PG, Zhou T,Wang W, Alvarez RD, Grizzle WE, et al. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecol Oncol 2006; 101:46-54.
33. Marini P, Denzinger S, Schiller D, Kauder S, Welz S, Humphreys R, et al. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 2006; 25:5145-5154. (Pubitemid 44285983)
34. Oliver PG, LoBuglio AF, Zinn KR, Kim H, Nan L, Zhou T, et al. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11. Clin Cancer Res 2008; 14: 2180-2189. (Pubitemid 351551131)
35. Hong GS, Jung YK. Caspase recruitment domain (CARD) as a bi-functional switch of caspase regulation and NF-kappaB signals. J Biochem Mol Biol 2002; 35:19-23.
36. Lechardeur D, Dougaparsad S, Nemes C, Lukacs GL. Oligomerization state of the DNA fragmentation factor in normal and apoptotic cells. J Biol Chem 2005; 280:40216-40225. (Pubitemid 41779159)
37. Rajandram R, Pat BK, Li J, Johnson DW, Gobe GC. Expression of apoptotic tumour necrosis factor receptor-associated factor, caspase recruitment domain and cell death-inducing DFF-45 effector genes in therapy-treated renal cell carcinoma. Nephrology 2009; 14: 205-212.
38. Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R, et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007; 13:6187-6194. (Pubitemid 350075080)
39. Wakelee HA, Patnaik A, Sikic BI, Mita M, Fox NL, Miceli R, et al. Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol 2010; 21: 376-381.